Interleukin-5 in the Pathophysiology of Severe Asthma

Frontiers in Physiology

Girolamo Pelaia²  Corrado Pelaia²  Giovanni Paoletti³  Giorgio Walter Canonica³  Francesca Racca³  Enrico Heffler³  Francesca Puggioni³ 

[1] Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy;Department of Medical and Surgical Sciences, University “Magna Græcia” of Catanzaro, Catanzaro, Italy;Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy;

关键词: IL-5;    eosinophils;    T2-high asthma;    mepolizumab;    reslizumab;    benralizumab;   

DOI  :  10.3389/fphys.2019.01514

来源: DOAJ

【 摘 要 】

Interleukin-5 (IL-5) exerts a central pathogenic role in differentiation, recruitment, survival, and degranulation of eosinophils. Indeed, during the last years, significant advances have been made in our understanding of the cellular and molecular mechanisms underlying the powerful actions of IL-5 finalized to the induction, maintenance, and amplification of eosinophilic inflammation. Therefore, IL-5 is a suitable target for add-on biological therapies based on either IL-5 inhibition (mepolizumab, reslizumab) or blockade of its receptor (benralizumab). These modern treatments can result in being definitely beneficial for patients with severe type 2 (T2)-high eosinophilic asthma, refractory to conventional anti-inflammatory drugs such as inhaled and even systemic corticosteroids.

【 授权许可】

Unknown